Testing luspatercept for low-risk MDS with low hemoglobin
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have MDS diagnosed by WHO standards
- Your MDS is “lower risk” (IPSS LOW or INT-1) and is not del(5q)
- Your anemia is low (hemoglobin under 9 g/dL) or you need regular blood transfusions
- You have tried ESA (or you cannot use ESA) and did not respond or later relapse without disease getting worse
- Your kidneys and liver blood tests are good enough (kidney: creatinine < 1.5x normal and clearance ≥ 40 mL/min; liver: bilirubin and liver enzymes < 1.5x normal)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
This trial tests a drug called luspatercept to see if it can improve red blood cell production in people with certain rare inherited anemias. If you have one of these anemias and have low hemoglobin, this study might help you reduce or avoid blood transfusions.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.